Structure via PubChem · Public domain (PubChem)
opicapone
Sign in to saveAlso known as BIA 9-1067, compound 37d [PMID: 20334432]
Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.
Key facts
- Drug.UNII
- Y5929UIJ5N
- Drug.image
- Opicapone.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Ongentys, Ontilyv
- Drug.DailyMedID
- Opicapone
- Drug.pregnancy_AU
- B2
- Drug.pregnancy_category
- Not recommended
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N04
- Drug.ATC_suffix
- BX04
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- ~20%
- Drug.protein_bound
- 99.9%
- Drug.metabolism
- Mainly sulfation, also reduction, glucuronidation, methylation
via Wikipedia infobox
Chemical data
- Formula
- C15H10Cl2N4O6
- Molecular weight
- 413.2 g/mol
- IUPAC name
- (4Z)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-2H-1,2,4-oxadiazol-5-ylidene]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-one
- SMILES
- CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=N/C(=C/3\C=C(C(=O)C(=C3)O)[N+](=O)[O-])/ON2
- InChIKey
- HVGGGVAREUUJQV-CHHVJCJISA-N
- XLogP
- 2.1
- Polar surface area
- 142 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 411.997739
Show 4 more facts
- canonical SMILES
- Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1
- chemical formula
- C₁₅H₁₀Cl₂N₄O₆
- Commons category
- Opicapone
- defined daily dose
- 50
via Wikidata · CC0
~9 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- References
- Further reading
Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor.
The most common side effects are dyskinesia (difficulty controlling movement), constipation, increased blood creatine kinase, hypotension/syncope, and decreased weight.
Excerpted from Wikipedia’s “opicapone” article, available under the CC BY-SA 4.0 licence.